Harrow Health (HROW) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 12, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-35814
Entity Registrant Name	Harrow, Inc.
Entity Central Index Key	0001360214
Entity Tax Identification Number	45-0567010
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1A Burton Hills Blvd.
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37215
City Area Code	(615)
Local Phone Number	733-4730
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,614,718
Entity Listing, Par Value Per Share	$ 0.001
Common Stock, $0.001 par value per share [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	HROW
Security Exchange Name	NASDAQ
8.625% Senior Notes due 2026 [Member]
Title of 12(b) Security	8.625% Senior Notes due 2026
Trading Symbol	HROWL
Security Exchange Name	NASDAQ
11.875% Senior Notes due 2027 [Member]
Title of 12(b) Security	11.875% Senior Notes due 2027
Trading Symbol	HROWM
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 72,601,000	$ 74,085,000
Investment in Eton Pharmaceuticals		8,681,000
Accounts receivable, net	53,734,000	36,261,000
Inventories	10,156,000	10,867,000
Prepaid expenses and other current assets	10,571,000	9,588,000
Total current assets	147,062,000	139,482,000
Property, plant and equipment, net	3,625,000	3,521,000
Capitalized software costs, net	1,869,000	2,138,000
Operating lease right-of-use assets, net	9,379,000	6,785,000
Intangible assets, net	189,272,000	159,906,000
Goodwill	332,000	332,000
TOTAL ASSETS	351,539,000	312,164,000
Current liabilities
Accounts payable and accrued expenses	25,277,000	24,581,000
Contingent consideration payable	37,000,000
Accrued rebates and copay assistance	24,899,000	18,432,000
Accrued payroll and related liabilities	7,185,000	5,450,000
Deferred revenue and customer deposits	137,000	75,000
Current portion of operating lease obligations	507,000	806,000
Total current liabilities	95,005,000	49,344,000
Operating lease obligations, net of current portion	9,500,000	6,524,000
Accrued expenses, net of current portion	2,713,000	2,713,000
Deferred tax liability	643,000
Notes payable, net of unamortized debt discounts	186,057,000	183,172,000
TOTAL LIABILITIES	293,918,000	241,753,000
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 35,611,365 and 35,168,260 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	35,000	35,000
Additional paid-in capital	216,103,000	204,635,000
Accumulated deficit	(158,162,000)	(133,904,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY	57,976,000	70,766,000
Noncontrolling interests	(355,000)	(355,000)
TOTAL STOCKHOLDERS’ EQUITY	57,621,000	70,411,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 351,539,000	$ 312,164,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	35,611,365	35,168,260
Common stock, shares outstanding	35,611,365	35,168,260

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 49,257,000	$ 34,265,000	$ 132,783,000	$ 93,838,000
Cost of sales	(12,018,000)	(10,067,000)	(35,110,000)	(28,338,000)
Gross profit	37,239,000	24,198,000	97,673,000	65,500,000
Operating expenses:
Selling, general and administrative	33,645,000	21,033,000	94,275,000	56,878,000
Research and development	2,273,000	1,421,000	7,475,000	3,316,000
Total operating expenses	35,918,000	22,454,000	101,750,000	60,194,000
Income (loss) from operations	1,321,000	1,744,000	(4,077,000)	5,306,000
Other (expense) income:
Interest expense, net	(5,525,000)	(5,749,000)	(16,411,000)	(16,200,000)
Investment (loss) gain from Eton Pharmaceuticals		1,348,000	(3,171,000)	2,676,000
Loss on extinguishment of debt				(5,465,000)
Other income (expenses), net	4,000	(195,000)	76,000	(344,000)
Total other expense, net	(5,521,000)	(4,596,000)	(19,506,000)	(19,333,000)
Loss before income taxes	(4,200,000)	(2,852,000)	(23,583,000)	(14,027,000)
Provision for income taxes	(20,000)	(1,539,000)	(675,000)	(1,236,000)
Net loss	$ (4,220,000)	$ (4,391,000)	$ (24,258,000)	$ (15,263,000)
Basic net loss per share of common stock	$ (0.12)	$ (0.13)	$ (0.68)	$ (0.48)
Diluted net loss per share of common stock	$ (0.12)	$ (0.13)	$ (0.68)	$ (0.48)
Weighted average number of shares of common stock outstanding, basic	35,702,200	34,255,197	35,597,409	31,689,947
Weighted average number of shares of common stock outstanding, diluted	35,702,200	34,255,197	35,597,409	31,689,947
Product Sales, Net [Member]
Revenues:
Total revenues	$ 49,019,000	$ 31,809,000	$ 132,398,000	$ 81,804,000
Other Revenues [Member]
Revenues:
Total revenues	$ 238,000	$ 2,456,000	$ 385,000	$ 12,034,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 30,000	$ 137,058,000	$ (109,493,000)	$ 27,595,000	$ (355,000)	$ 27,240,000
Balance, shares at Dec. 31, 2022	29,901,530
Public offering, net of offering costs	$ 4,000	64,516,000		64,520,000		64,520,000
Public offering, net of offering costs, shares	3,887,324
Exercise of consultant stock-based options		85,000		85,000		85,000
Exercise of consultant stock-based options, shares	10,000
Exercise of employee stock-based options		270,000		270,000		270,000
Exercise of employee stock-based options, shares	219,246
Vesting of RSUs and PSUs	$ 2,000	(2,000)
Vesting of RSUs, shares	1,810,673
Shares withheld related to net share settlement of equity awards	$ (1,000)	(12,970,000)		(12,971,000)		(12,971,000)
Shares withheld related to net share settlement of equity awards, shares	(711,152)
Stock-based compensation expense		11,521,000		11,521,000		11,521,000
Net loss			(15,263,000)	(15,263,000)		(15,263,000)
Balance at Sep. 30, 2023	$ 35,000	200,478,000	(124,756,000)	75,757,000	(355,000)	75,402,000
Balance, shares at Sep. 30, 2023	35,117,621
Balance at Jun. 30, 2023	$ 30,000	142,742,000	(120,365,000)	22,407,000	(355,000)	22,052,000
Balance, shares at Jun. 30, 2023	30,276,938
Public offering, net of offering costs	$ 4,000	64,516,000		64,520,000		64,520,000
Public offering, net of offering costs, shares	3,887,324
Exercise of employee stock-based options		18,000		18,000		18,000
Exercise of employee stock-based options, shares	2,430
Shares withheld related to net share settlement of equity awards	$ (1,000)	(11,272,000)		(11,273,000)		(11,273,000)
Shares withheld related to net share settlement of equity awards, shares	(616,984)
Stock-based compensation expense		4,476,000		4,476,000		4,476,000
Net loss			(4,391,000)	(4,391,000)		(4,391,000)
Vesting of PSUs	$ 2,000	(2,000)
Vesting of RSUs, shares	1,567,913
Balance at Sep. 30, 2023	$ 35,000	200,478,000	(124,756,000)	75,757,000	(355,000)	75,402,000
Balance, shares at Sep. 30, 2023	35,117,621
Balance at Dec. 31, 2023	$ 35,000	204,635,000	(133,904,000)	70,766,000	(355,000)	70,411,000
Balance, shares at Dec. 31, 2023	35,168,260
Public offering, net of offering costs, shares	32,580
Exercise of consultant stock-based options, shares	39,237
Exercise of employee stock-based options		1,005,000		1,005,000		1,005,000
Exercise of employee stock-based options, shares	248,175
Shares withheld related to net share settlement of equity awards		(2,362,000)		(2,362,000)		(2,362,000)
Shares withheld related to net share settlement of equity awards, shares	(137,587)
Stock-based compensation expense		12,825,000		12,825,000		12,825,000
Net loss			(24,258,000)	(24,258,000)		(24,258,000)
Vesting of RSUs
Vesting of RSUs, shares	332,517
Balance at Sep. 30, 2024	$ 35,000	216,103,000	(158,162,000)	57,976,000	(355,000)	57,621,000
Balance, shares at Sep. 30, 2024	35,611,365
Balance at Jun. 30, 2024	$ 35,000	212,439,000	(153,942,000)	58,532,000	(355,000)	58,177,000
Balance, shares at Jun. 30, 2024	35,479,492
Exercise of employee stock-based options		484,000		484,000		484,000
Exercise of employee stock-based options, shares	160,980
Shares withheld related to net share settlement of equity awards		(1,205,000)		(1,205,000)		(1,205,000)
Shares withheld related to net share settlement of equity awards, shares	(29,107)
Stock-based compensation expense		4,385,000		4,385,000		4,385,000
Net loss			(4,220,000)	(4,220,000)		(4,220,000)
Balance at Sep. 30, 2024	$ 35,000	$ 216,103,000	$ (158,162,000)	$ 57,976,000	$ (355,000)	$ 57,621,000
Balance, shares at Sep. 30, 2024	35,611,365

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (24,258,000)	$ (15,263,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment and software development costs	1,382,000	1,095,000
Amortization of intangible assets	7,708,000	7,634,000
Amortization of operating lease right-of-use assets	636,000	541,000
(Recovery of) provision for credit losses	(20,000)	68,000
Amortization of debt issuance costs and debt discount	2,985,000	2,568,000
Investment loss (gain) from investment in Eton	3,171,000	(2,676,000)
Loss on extinguishment of debt		5,465,000
Loss on disposal of intangible assets		22,000
Stock-based compensation	12,825,000	11,521,000
Deferred income tax	643,000
Changes in assets and liabilities:
Accounts receivable	(17,453,000)	(12,287,000)
Inventories	711,000	(2,383,000)
Prepaid expenses and other current assets	(983,000)	(4,079,000)
Accounts payable, accrued expenses, accrued rebates and copay assistance	6,433,000	1,584,000
Accrued payroll and related liabilities	1,735,000	1,294,000
Deferred revenue and customer deposits	62,000	40,000
NET CASH USED IN OPERATING ACTIVITIES	(4,423,000)	(4,856,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from sale of investment in Eton Pharmaceuticals	5,510,000
Investment in patent and trademark assets	(74,000)
Purchase of product NDAs and related patents		(151,084,000)
Purchases of property, plant and equipment	(1,040,000)	(1,266,000)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	4,396,000	(152,350,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 11.875% notes payable, net of costs		4,961,000
Proceeds from Oaktree Loan, net of costs		73,552,000
Payment of debt issuance costs	(100,000)
Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options	(2,362,000)	(12,971,000)
Proceeds from exercise of stock options	1,005,000	355,000
Proceeds from B. Riley senior secured note, net of costs		55,879,000
Repayment of B. Riley senior secured note		(59,750,000)
Proceeds from public offering of common stock, net of costs		64,520,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(1,457,000)	126,546,000
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,484,000)	(30,660,000)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	74,085,000	96,270,000
CASH AND CASH EQUIVALENTS AT END OF PERIOD	72,601,000	65,610,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest	15,553,000	12,279,000
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of deferred financing costs		1,950,000
Accrual of exit fee related to Oaktree Loan		2,713,000
Insurance premium financed		1,321,000
Purchase of product NDAs associated with contingent consideration payable	37,000,000
Purchase of property, plant and equipment included in accounts payable and accrued expenses	177,000	11,000
Right-of-use assets obtained in exchange for new operating lease obligations	$ 3,230,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Sep. 30, 2023
Statement of Cash Flows [Abstract]
Notes payable percent	11.875%

DESCRIPTION OF BUSINESS AND BAS

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority owned subsidiaries. Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity. The Company consolidates (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the three and nine months ended September 30, 2024 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. During the period ended September 30, 2024, the Company identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments. Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations. Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. The accounts receivable balance on the Company’s condensed consolidated balance sheet as of September 30, 2024 was $ 53,734,000 281,000 SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2024 $ 371,000 Change in expected credit losses (20,000 ) Write-offs, net of recoveries (70,000 ) Balance at September 30, 2024 $ 281,000 Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At December 31, 2023, the Company measured its investment in Eton Pharmaceuticals, Inc. (“Eton”) on a recurring basis. The Company’s investment in Eton was classified as a Level 1 as the fair value was determined using quoted market prices in active markets for the same securities. As of December 31, 2023, the fair market value of the Company’s investment in Eton was $ 8,681,000 3.00 436,000 5,510,000 3,171,000 The Company’s 2026 Notes (as defined in Note 11) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as described in Note 11) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 11) is carried at face value less the original issue discount and unamortized debt issuance costs on the condensed consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures. The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE September 30, 2024 December 31, 2023 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 73,804,000 $ 76,830,000 $ 73,218,000 $ 70,260,000 2027 Notes $ 37,950,000 $ 43,084,000 $ 37,413,000 $ 40,363,000 Oaktree Loan $ 74,303,000 $ 78,663,000 $ 72,541,000 $ 76,627,000 The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, contingent consideration payable, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the operating lease liabilities approximate their respective fair values. Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”), and market-based vesting performance stock units (“PSUs”), outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs, and unvested PSUs were 4,411,488 4,588,982 195,696 244,352 The following table shows the computation of basic and diluted net loss per share of common stock: SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Numerator – net loss $ (4,220,000 ) $ (4,391,000 ) $ (24,258,000 ) $ (15,263,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 35,702,200 34,255,197 35,597,409 31,689,947 Net loss per share, basic and diluted $ (0.12 ) $ (0.13 ) $ (0.68 ) $ (0.48 ) Income Taxes The Company’s effective tax rate was (2.95) (8.81) 21 As of September 30, 2024 and December 31, 2023, there were no Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 2,334,256 46 On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. The Company has no investments other than its common stock and preferred stock positions in Melt and no other requirements to advance funds to Melt. The following table summarizes the Company’s investments in Melt as of September 30, 2024: SCHEDULE OF INVESTMENT Cost Share of Equity Method Net Carrying Basis Losses Value Common stock $ 5,810,000 $ (5,810,000 ) $ - Preferred stock 18,397,000 (18,397,000 ) - $ 24,207,000 $ (24,207,000 ) $ - See Note 4 for more information and related party disclosure regarding Melt. Accounting Guidance Issued but Not Adopted at September 30, 2024 In October 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-06, Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures,

REVENUES

REVENUES	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUES	NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenue from Contracts with Customers Product Revenues The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s pharmacy services include: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following: 1. Identify the contract(s) with a customer: 2. Identify the performance obligations in the contract: 3. Determine the transaction price: 4. Allocate the transaction price to the performance obligations in the contract: 5. Recognize revenue when (or as) the entity satisfies a performance obligation: Revenues From Transfer of Acquired Product Sales and Profits The Company has entered into agreements whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic products from other pharmaceutical companies (the “Sellers”). During a temporary, transition period, the Sellers continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The revenue recognized by the Company from the transfer of net profit was recognized at the time profit from the product sales were calculated by the Sellers and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. On a quarterly basis, the Sellers invoice the Company for all credits and reimbursements (“Chargebacks”) made to customers related to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net sales and profit transferred. The estimated Chargebacks are recorded as a reduction in revenues from transfer of acquired product sales and profits in the Company’s consolidated statements of operations, and recorded as a reduction to accounts receivable in the consolidated balance sheets, at the time the revenue is recognized. Intellectual Property License and Related Arrangements Revenues As of September 30, 2024, the Company held five intellectual property licenses and related arrangements pursuant to which the Company has agreed to license or sell to a customer the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time that the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverables are delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source consisted of the following: SCHEDULE OF DISAGGREGATED REVENUE For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Product sales, net $ 49,019,000 $ 31,809,000 $ 132,398,000 $ 81,804,000 Other revenues 238,000 2,456,000 385,000 12,034,000 Total revenues $ 49,257,000 $ 34,265,000 $ 132,783,000 $ 93,838,000 Deferred revenue and customer deposits at September 30, 2024 and December 31, 2023 were $ 137,000 75,000

INVESTMENT IN, AND NOTE RECEIVA

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS	NOTE 4. INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an Asset Purchase Agreement with Melt (the “Melt APA”). Pursuant to the terms of the Melt APA, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt APA, Melt is required to make mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In February 2019, the Company entered into a Management Services Agreement (the “Melt MSA”), whereby the Company provided to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt was required to pay the Company a monthly amount of $ 10,000 0 89,000 As of both 228,000 In March 2024, Melt completed its Series B Preferred Stock financing which raised gross proceeds of approximately $ 23,900,000 The Company’s Chief Executive Officer, Mark L. Baum, is a member of the Melt board of directors. The Melt board of directors consists of five members, including Mr. Baum. Mr. Baum is the only representative of the Company on Melt’s board of directors. The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT For the Nine Months Ended September 30, 2024 2023 Revenues, net $ - $ - Loss from operations $ (11,334,000 ) $ (3,663,000 ) Net loss $ (10,942,000 ) $ (5,407,000 ) The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET At September 30, At December 31, 2024 2023 Current assets $ 7,366,000 $ 13,404,000 Total assets $ 7,366,000 $ 13,404,000 Total liabilities $ 5,242,000 $ 3,922,000 Total stockholders’ equity 2,124,000 9,482,000 Total liabilities and stockholders’ equity $ 7,366,000 $ 13,404,000

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories was as follows: SCHEDULE OF INVENTORIES At September 30, 2024 At December 31, 2023 Raw materials $ 5,306,000 $ 5,477,000 Work in progress 176,000 54,000 Finished goods 4,674,000 5,336,000 Total inventories $ 10,156,000 $ 10,867,000

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS At September 30, 2024 At December 31, 2023 Prepaid insurance $ 1,639,000 $ 1,241,000 Prepaid computer software licenses and related expenses 619,000 1,613,000 Prefunded co-pay assistance 4,514,000 - Other prepaid expenses 1,749,000 906,000 Receivable due from Melt 228,000 228,000 Prepaid FY 2024 Prescription Drug User (“PDUFA”) fees - 3,438,000 Deferred Oaktree Loan commitment fee 372,000 409,000 Deposits and other current assets 1,450,000 1,753,000 Total prepaid expenses and other current assets $ 10,571,000 $ 9,588,000

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 7. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT At September 30, 2024 At December 31, 2023 Property, plant and equipment: Computer hardware $ 1,477,000 $ 1,322,000 Furniture and equipment 965,000 936,000 Lab and pharmacy equipment 5,304,000 4,564,000 Leasehold improvements 6,899,000 6,771,000 Property, plant and equipment, gross 14,645,000 13,593,000 Accumulated depreciation (11,020,000 ) (10,072,000 ) Property, plant and equipment, net $ 3,625,000 $ 3,521,000 For the three and nine months ended September 30, 2024, depreciation related to property, plant and equipment was $ 351,000 948,000 290,000 743,000

CAPITALIZED SOFTWARE COSTS

CAPITALIZED SOFTWARE COSTS	9 Months Ended
	Sep. 30, 2024
Capitalized Software Costs
CAPITALIZED SOFTWARE COSTS	NOTE 8. CAPITALIZED SOFTWARE COSTS Capitalized software costs consisted of the following: SCHEDULE OF CAPITALIZED SOFTWARE COSTS At September 30, 2024 At December 31, 2023 Capitalized software costs: Capitalized internal-use software development costs $ 3,366,000 $ 2,780,000 Acquired third-party software license for internal-use 205,000 159,000 Total gross capitalized software for internal-use 3,571,000 2,939,000 Accumulated amortization (1,702,000 ) (1,268,000 ) Capitalized internal-use software in process - 467,000 Total capitalized software costs net $ 1,869,000 $ 2,138,000 The Company recorded amortization expense of $ 146,000 434,000 115,000 352,000

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	NOTE 9. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at September 30, 2024 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS Amortization Periods (in years) Cost Accumulated Amortization Net Carrying Value Patents 7 19 $ 610,000 $ (207,000 ) $ 403,000 Licenses 7 20 50,000 (36,000 ) 14,000 Trademarks Indefinite 226,000 - 226,000 Acquired NDAs 4 15 207,398,000 (18,899,000 ) 188,499,000 Customer relationships 3 15 596,000 (539,000 ) 57,000 Trade name 5 75,000 (7,000 ) 68,000 Non-competition clause 3 4 50,000 (50,000 ) - State pharmacy licenses 25 8,000 (3,000 ) 5,000 $ 209,013,000 $ (19,741,000 ) $ 189,272,000 Amortization expense for intangible assets was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Patents $ 19,000 $ 22,000 $ 47,000 $ 65,000 Licenses 34,000 2,000 34,000 7,000 Acquired NDAs 2,547,000 2,551,000 7,606,000 7,526,000 Customer relationships 3,000 9,000 19,000 36,000 Trade name 1,000 - 1,000 - State pharmacy licenses 1,000 - 1,000 - Amortization expense of intangible assets $ 2,605,000 $ 2,584,000 $ 7,708,000 $ 7,634,000 Estimated future amortization expenses for the Company’s intangible assets at September 30, 2024 was as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE Remainder of 2024 $ 4,025,000 2025 16,630,000 2026 16,630,000 2027 16,281,000 2028 15,933,000 Thereafter 119,547,000 Intangible assets $ 189,046,000 In connection with an asset purchase agreement between Novartis and the Company, the Company is required to make a milestone payment following the release of the first commercially available batch of TRIESENCE . During the three months ended September 30, 2024, the Company determined that it was probable the first commercial batch would be released and, as such, recognized the $ 37,000,000 There were no

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES At September 30, At December 31, 2024 2023 Accounts payable $ 23,202,000 $ 21,424,000 Accrued insurance premium 21,000 873,000 Other accrued payments 106,000 306,000 Accrued interest (see Note 11) 1,948,000 1,978,000 Accrued exit fee for Oaktree Loan (see Note 11) 2,713,000 2,713,000 Total accounts payable and accrued expenses $ 27,990,000 $ 27,294,000 Less: current portion (25,277,000 ) (24,581,000 ) Non-current total accrued expenses $ 2,713,000 $ 2,713,000

DEBT

DEBT	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
DEBT	NOTE 11. DEBT Oaktree Loan Due 2026 In March 2023, the Company entered into a Credit Agreement and Guaranty, (the “Oaktree Loan”) with Oaktree Fund Administration, LLC, as administrative agent for the lenders (“Oaktree”), providing for a senior secured term loan facility to the Company with a principal amount of up to $ 100,000,000 65,000,000 12,500,000 100,000,000 112,500,000 35,000,000 30,000,000 2 Interest expense related to the Oaktree Loan totaled $ 3,026,000 8,923,000 656,000 1,861,000 $ 2,995,000 5,660,000 $ 567,000 1,093,000 The Oaktree Loan carries an exit fee equal to 3.5 2,713,000 2,713,000 HROWM – 11.875% Senior Notes Due 2027 In December 2022 and January 2023, the Company closed offerings of $ 40,250,000 11.875 December 2027 Interest expense related to the 2027 Notes totaled $ 1,376,000 4,121,000 181,000 537,000 1,375,000 4,141,000 180,000 556,000 HROWL – 8.625% Senior Notes Due 2026 In April and September 2021, the Company closed offerings (including an over-allotment exercise in May 2021) of $ 75,000,000 aggregate principal amount of 8.625 % senior notes due April 2026 (the “2026 Notes”). In terest expense related to the 2026 Notes totaled $ 1,814,000 and $ 5,438,000 for the three and nine months ended September 30, 2024, respectively, and included amortization of debt issuance costs and debt discount of $ 197,000 and $ 587,000 , respectively. Interest expense related to the 2026 Notes totaled $ 1,814,000 and $ 5,436,000 for the three and nine months ended September 30, 2023, respectively, and included amortization of debt issuance costs and debt discount of $ 197,000 and $ 585,000 , respectively. A summary of the Company’s debt is described as follows: SCHEDULE OF LONG TERM DEBT At September 30, At December 31, 2024 2023 8.625 April 2026 $ 75,000,000 $ 75,000,000 11.875 December 2027 40,250,000 40,250,000 Oaktree Loan due January 2026 77,500,000 77,500,000 Notes payable gross 192,750,000 192,750,000 Less: Unamortized debt issuance costs, net of premium (6,693,000 ) (9,578,000 ) Notes payable net $ 186,057,000 $ 183,172,000 For the three and nine months ended September 30, 2024, the total effective interest rate of the Company’s debt was 11.03 11.17 10.78 10.91 . At September 30, 2024, future minimum payments under the Company’s debt were as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES Amount Remainder of 2024 $ 5,166,000 2025 20,560,000 2026 159,895,000 2027 45,030,000 Total minimum payments 230,651,000 Less: amount representing interest payments (37,901,000 ) Notes payable, gross principal amount due 192,750,000 Less: unamortized debt issuance costs, net of premium (6,693,000 ) Notes payable, net of unamortized debt issuance costs $ 186,057,000

LEASES

LEASES	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
LEASES	NOTE 12. LEASES The Company leases office and laboratory space under non-cancellable operating leases listed below. These lease agreements have remaining terms between one seven years ● An operating lease for 5,789 March 2025 ● An operating lease for 38,153 July 2027 1,400 July 2027 8,900 2,861 ● An operating lease for 5,500 December 2024 option to extend the term for two additional five-year periods ● An operating lease for 11,552 September 2027 ● In March 2024, the Company entered into an operating lease for 17,625 seven option to extend the term for two additional five-year periods 2,853,000 At September 30, 2024, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 7.85 10.4 During the three and nine months ended September 30, 2024, cash paid for amounts included for the operating lease liabilities was $ 327,000 972,000 310,000 921,000 414,000 1,053,000 309,000 926,000 Future lease payments under operating leases as of September 30, 2024 were as follows : SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES Operating Leases Remainder of 2024 $ 329,000 2025 1,386,000 2026 1,767,000 2027 1,641,000 2028 1,342,000 Thereafter 7,971,000 Total minimum lease payments 14,436,000 Less: amount representing interest payments (4,429,000 ) Total operating lease obligations 10,007,000 Less: current portion, operating lease obligations (507,000 ) Operating lease obligations, net of current portion $ 9,500,000

STOCKHOLDERS_ EQUITY AND STOCK-

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION	NOTE 13. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Common Stock During the nine months ended September 30, 2024, the Company issued 141,628 1,005,000 141,628 1.70 25.86 During the nine months ended September 30, 2024, the Company issued 32,580 39,237 1.70 8.00 During the nine months ended September 30, 2024, the Company issued 44,860 90,000 7.37 29,107 1,205,000 During the nine months ended September 30, 2024, 45,000 26,520 18,480 197,000 During the nine months ended September 30, 2024, 150,000 90,164 59,836 638,000 During the nine months ended September 30, 2024, 30,000 17,384 12,616 135,000 During the nine months ended September 30, 2024, 50,000 32,452 17,548 187,000 During the nine months ended September 30, 2024, the Company issued 57,517 3,872 During the nine months ended September 30, 2024, 34,008 During the nine months ended September 30, 2024, 3,667 Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of September 30, 2024, the 2017 Plan provides for the issuance of a maximum of 6,000,000 53,344 Stock Options A summary of stock option activity under the Plans for the nine months ended September 30, 2024 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Options outstanding – January 1, 2024 2,711,317 $ 6.25 Options granted 140,000 $ 14.72 Options exercised (270,865 ) $ 7.12 Options cancelled/forfeited (100,063 ) $ 13.56 Options outstanding – September 30, 2024 2,480,389 $ 6.33 3.44 $ 95,807,000 Options exercisable 2,218,148 $ 5.50 2.80 $ 87,536,000 Options vested and expected to vest 2,444,924 $ 6.21 3.36 $ 94,733,000 The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise price lower than the market price on September 30, 2024, based on the closing price of the Company’s common stock of $ 44.96 During the nine months ended September 30, 2024, the Company granted stock options to certain employees. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of ten years. Vesting terms for options granted to employees during the nine months ended September 30, 2024 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10 The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2024 Weighted-average fair value of options granted $ 9.64 Expected terms (in years) 6.11 Expected volatility 67.78 72.95 % Risk-free interest rate 3.72 4.48 % Dividend yield - The following table summarizes information about stock options outstanding and exercisable at September 30, 2024: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.47 1.70 31,942 2.96 $ 1.68 31,942 $ 1.68 $ 1.73 250,000 3.25 $ 1.73 250,000 $ 1.73 $ 2.23 270,000 2.34 $ 2.23 270,000 $ 2.23 $ 2.40 2.60 14,068 2.33 $ 2.57 14,068 $ 2.57 $ 3.95 308,500 1.50 $ 3.95 308,500 $ 3.95 $ 4.49 5.72 92,300 4.86 $ 5.53 92,300 $ 5.53 $ 6.30 285,000 4.39 $ 6.30 285,000 $ 6.30 $ 6.75 7.26 46,036 7.76 $ 6.85 18,162 $ 6.77 $ 7.30 274,500 5.26 $ 7.30 274,500 $ 7.30 $ 7.60 39.63 908,043 3.31 $ 9.63 673,676 $ 8.04 $ 1.47 39.63 2,480,389 3.44 $ 6.33 2,218,148 $ 5.50 As of September 30, 2024, there was approximately $ 2,071,000 2.83 160,000 416,000 154,000 617,000 The intrinsic value of options exercised during the nine months ended September 30, 2024 was $ 6,651,000 Restricted Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including time-based and performance-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2024 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY Number of Shares Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2024 363,029 $ 9.23 RSUs granted 319,081 23.93 RSUs vested (312,674 ) 9.84 RSUs cancelled/forfeited (6,250 ) 8.10 RSUs unvested - September 30, 2024 363,186 $ 21.63 As of September 30, 2024, the total unrecognized compensation expense related to unvested RSUs was approximately $ 7,324,000 2 587,000 1,494,000 374,000 789,000 Performance Stock Units (Market-Based Vesting) A summary of the Company’s PSU activity and related information for the nine months ended September 30, 2024 is as follows: SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY Number of Shares Weighted Average Grant Date Fair Value PSUs unvested – January 1, 2024 1,567,913 $ 18.56 PSUs granted - PSUs vested - PSUs cancelled/forfeited - PSUs unvested – September 30, 2024 1,567,913 $ 18.56 As of September 30, 2024, the total unrecognized compensation expense related to unvested PSUs was approximately $ 7,277,000 0.51 3,638,000 10,915,000 3,948,000 10,115,000 Stock-Based Compensation Summary The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Employees - selling, general and administrative $ 3,728,000 $ 3,784,000 $ 10,832,000 $ 9,719,000 Employees - research and development 422,000 475,000 1,300,000 1,224,000 Directors - selling, general and administrative 199,000 200,000 601,000 528,000 Consultants - selling, general and administrative 36,000 17,000 92,000 50,000 Total $ 4,385,000 $ 4,476,000 $ 12,825,000 $ 11,521,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14. COMMITMENTS AND CONTINGENCIES Legal General and Other In the ordinary course of business, the Company is involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. The Company describes legal proceedings and other matters that are/were significant or that it believes could become significant in this note. The Company records accruals for loss contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of a liability that has been accrued previously. The Company’s legal proceedings involve various aspects of its business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. Typically, a number of the matters pending against the Company are at early stages of the legal process, which in complex proceedings of the sort the Company faces often extend for several years. While it is not possible to accurately predict or determine the eventual outcomes of matters that have not concluded, an adverse determination in one or more of the matters (whether discussed in this note or not) currently pending may have a material adverse effect on the Company’s condensed consolidated results of operations, financial position or cash flows. Ocular Science, Inc. et. al In July 2021, ImprimisRx, LLC, a subsidiary of the Company, filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. (together, “OSRX”) in the U.S. District Court for the Southern District of California, asserting claims for copyright infringement, trademark infringement, unfair competition and false advertising (Lanham Act). Since July 2021, the complaint has been amended and OSRX added counterclaims alleging ImprimisRx, LLC is violating the Lanham Act with false advertising. The Court granted cross motions for summary judgement on each party’s Lanham Act claims thus leaving only ImprimisRx, LLC’s copyright infringement, trademark infringement and unfair competition claims for trial. ImprimisRx, LLC is seeking damages from OSRX. The trial associated with this matter began during the month of November 2024 and is ongoing as of the date of this Quarterly Report. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. Indemnities In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. Several of the Company’s asset purchase and license agreements contain customary representations, warranties, covenants and confidentiality provisions, and also contain mutual indemnification obligations related primarily to performance under the respective agreements. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Asset Purchase, License and Related Agreements FDA Approved Product Acquisitions In recent years, the Company has acquired commercial and product rights to various FDA approved ophthalmic medications and products through asset purchase, licenses, supply and/or other related agreements. In general, in exchange for product and commercial rights these agreements provide the counterparties with certain upfront and contingent milestone payments typically related to certain annual sales amounts and manufacturing events, and in certain cases, per unit transfer prices and royalties on sales of some of the products. During the three and nine months ended September 30, 2024, $ 730,000 and $ 2,040,000 , respectively, were incurred under these agreements as royalty expenses, and $ 220,000 and $ 705,000 , respectively, during the same periods in 2023. During the three and nine months ended September 30, 2024, $ 0 was incurred under these agreements related to upfront and milestone payments under these agreements. During the three and nine months ended September 30, 2023, the Company amended the Sintetica Agreement to allow for early payment of previously accrued amounts for commercial related milestones associated with sales of IHEEZO in exchange for a $ 550,000 550,000 4,450,000 Formulation Acquisitions The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors, innovator companies and related parties (the “Inventors”) through multiple asset purchase agreements and license agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of these intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of a milestone, generally consisting of: (1) a payment payable within 30 to 45 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. During the three and nine months ended September 30, 2024, $ 453,000 949,000 300,000 951,000 Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and marketing representation services to Harrow in select geographies in the U.S. in connection with the Company’s ophthalmic pharmaceutical compounded formulations or related products. Under the terms of the sales and marketing agreements, the Company was generally required to make commission payments equal to 10 14 0 130,000 Contract Manufacturing The Company has entered into manufacturing agreements with respect to third-party contract manufacturers for its FDA approved pharmaceutical products. Some of these contract manufacturing agreements require minimum annual order amounts. The Company has committed to pay approximately $ 2,728,000

SEGMENTS AND CONCENTRATIONS

SEGMENTS AND CONCENTRATIONS	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENTS AND CONCENTRATIONS	NOTE 15. SEGMENTS AND CONCENTRATIONS Prior to the three months ended September 30, 2024, the Company operated its business on the basis of a single two ● The Branded ● The ImprimisRx Segment contribution for the segments represents net revenues less cost of sales, certain general and administrative expenses, selling and marketing expenses, and research and development expenses. The Company does not evaluate the following items at the segment level: ● Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses. ● Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs. ● Other select revenues and operating expenses including research and development expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. Segment net revenues, segment operating expenses and segment contribution information consisted of the following: SCHEDULE OF SEGMENT NET REVENUES Branded ImprimisRx Consolidated Three Months Ended September 30, 2024 Branded ImprimisRx Consolidated Product sales, net $ 28,314,000 $ 20,705,000 $ 49,019,000 Other revenues 238,000 - 238,000 Total revenues 28,552,000 20,705,000 49,257,000 Cost of sales (5,169,000 ) (6,849,000 ) (12,018,000 ) Gross profit 23,383,000 13,856,000 37,239,000 Operating expenses: Selling, general and administrative 14,038,000 5,427,000 19,465,000 Research and development 212,000 84,000 296,000 Segment contribution $ 9,133,000 $ 8,345,000 17,478,000 Corporate 14,180,000 Research and development 1,977,000 Income from operations $ 1,321,000 Branded ImprimisRx Consolidated Three Months Ended September 30, 2023 Branded ImprimisRx Consolidated Product sales, net $ 12,040,000 $ 19,769,000 $ 31,809,000 Other revenues 2,456,000 - 2,456,000 Total revenues 14,496,000 19,769,000 34,265,000 Cost of sales (3,335,000 ) (6,732,000 ) (10,067,000 ) Gross profit 11,161,000 13,037,000 24,198,000 Operating expenses: Selling, general and administrative 1,930,000 7,703,000 9,633,000 Research and development 37,000 159,000 196,000 Segment contribution $ 9,194,000 $ 5,175,000 14,369,000 Corporate 11,400,000 Research and development 1,225,000 Income from operations $ 1,744,000 Branded ImprimisRx Consolidated Nine Months Ended September 30, 2024 Branded ImprimisRx Consolidated Product sales, net $ 69,395,000 $ 63,003,000 $ 132,398,000 Other revenues 385,000 - 385,000 Total revenues 69,780,000 63,003,000 132,783,000 Cost of sales (14,406,000 ) (20,704,000 ) (35,110,000 ) Gross profit 55,374,000 42,299,000 97,673,000 Operating expenses: Selling, general and administrative 36,034,000 17,364,000 53,398,000 Research and development 321,000 261,000 582,000 Segment contribution $ 19,019,000 $ 24,674,000 43,693,000 Corporate 40,877,000 Research and development 6,893,000 Loss from operations $ (4,077,000 ) Branded ImprimisRx Consolidated Nine Months Ended September 30, 2023 Branded ImprimisRx Consolidated Product sales, net $ 21,829,000 $ 59,975,000 $ 81,804,000 Other revenues 12,034,000 - 12,034,000 Total revenues 33,863,000 59,975,000 93,838,000 Cost of sales (8,396,000 ) (19,942,000 ) (28,338,000 ) Gross profit 25,467,000 40,033,000 65,500,000 Operating expenses: Selling, general and administrative 4,797,000 23,334,000 28,131,000 Research and development 37,000 560,000 597,000 Segment contribution $ 20,633,000 $ 16,139,000 36,772,000 Corporate 28,747,000 Research and development 2,719,000 Income from operations $ 5,306,000 All revenue is attributable to the United States. All long-lived assets at September 30, 2024 and December 31, 2023 were located in the United States. Revenues by segment are further described as follows: SCHEDULE OF REVENUES BY SEGMENT For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 IHEEZO $ 12,882,000 26 % $ 5,927,000 17 % $ 26,498,000 20 % $ 10,073,000 11 % VEVYE 5,186,000 11 % - - % 12,099,000 9 % - - % Other products (Anterior Segment) 10,256,000 21 % 6,605,000 19 % 30,808,000 23 % 13,205,000 14 % Other revenue, net 228,000 0 % 1,964,000 6 % 375,000 0 % 10,585,000 11 % Branded revenue, net 28,552,000 58 % 14,496,000 42 % 69,780,000 53 % 33,863,000 36 % ImprimisRx revenue, net 20,705,000 42 % 19,769,000 58 % 63,003,000 47 % 59,975,000 64 % Total revenues, net $ 49,257,000 100 % $ 34,265,000 100 % $ 132,783,000 100 % $ 93,838,000 100 % Other than IHEEZO, VEVYE, and one ImprimisRx product, no other products accounted for more than 10% of total revenues for the periods presented. Customer and Supplier Concentrations Substantially all of the Company’s Branded sales are made to a third-party logistics wholesaler who sells the products to the end-user. There were no customers who comprised more than 10 As of September 30, 2024 and December 31, 2023, accounts receivable from a single customer accounted for 64 80 46 42 35 23 The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 50 51 96 79

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to September 30, 2024 through the filing date of this Quarterly Report on Form 10-Q. Based on its evaluation, no events other than those described below need to be disclosed. In October 2024, the Company entered into the Second Amendment to Credit Agreement and Guaranty with Oaktree (“Second Amendment”). Upon satisfaction of certain conditions to funding, the Company drew down the principal amount of $ 30,000,000 30,000,000 37,000,000 150,000 30,000,000 107,500,000 In November 2024, the Company became aware of a cybersecurity incident that involved unauthorized access of an employee’s email account. Through this unauthorized access the threat actor was able to fraudulently divert Company funds to its bank account. The Company, along with its external cybersecurity experts, is continuing to work diligently to fully investigate and assess the impact of the incident and has notified, and is cooperating with, federal law enforcement. As the investigation of the incident is ongoing, the full scope, nature and impact of the incident are not yet fully known.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Segments	Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. During the period ended September 30, 2024, the Company identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments.
Risks, Uncertainties and Liquidity	Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.
Credit Losses	Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. The accounts receivable balance on the Company’s condensed consolidated balance sheet as of September 30, 2024 was $ 53,734,000 281,000 SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2024 $ 371,000 Change in expected credit losses (20,000 ) Write-offs, net of recoveries (70,000 ) Balance at September 30, 2024 $ 281,000
Fair Value Measurements	Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: ● Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available. ● Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method. At December 31, 2023, the Company measured its investment in Eton Pharmaceuticals, Inc. (“Eton”) on a recurring basis. The Company’s investment in Eton was classified as a Level 1 as the fair value was determined using quoted market prices in active markets for the same securities. As of December 31, 2023, the fair market value of the Company’s investment in Eton was $ 8,681,000 3.00 436,000 5,510,000 3,171,000 The Company’s 2026 Notes (as defined in Note 11) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as described in Note 11) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 11) is carried at face value less the original issue discount and unamortized debt issuance costs on the condensed consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures. The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE September 30, 2024 December 31, 2023 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 73,804,000 $ 76,830,000 $ 73,218,000 $ 70,260,000 2027 Notes $ 37,950,000 $ 43,084,000 $ 37,413,000 $ 40,363,000 Oaktree Loan $ 74,303,000 $ 78,663,000 $ 72,541,000 $ 76,627,000 The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, contingent consideration payable, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the operating lease liabilities approximate their respective fair values.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”), and market-based vesting performance stock units (“PSUs”), outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs, and unvested PSUs were 4,411,488 4,588,982 195,696 244,352 The following table shows the computation of basic and diluted net loss per share of common stock: SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Numerator – net loss $ (4,220,000 ) $ (4,391,000 ) $ (24,258,000 ) $ (15,263,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 35,702,200 34,255,197 35,597,409 31,689,947 Net loss per share, basic and diluted $ (0.12 ) $ (0.13 ) $ (0.68 ) $ (0.48 )
Income Taxes	Income Taxes The Company’s effective tax rate was (2.95) (8.81) 21 As of September 30, 2024 and December 31, 2023, there were no
Investment in Melt Pharmaceuticals, Inc. – Related Party	Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 2,334,256 46 On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. The Company has no investments other than its common stock and preferred stock positions in Melt and no other requirements to advance funds to Melt. The following table summarizes the Company’s investments in Melt as of September 30, 2024: SCHEDULE OF INVESTMENT Cost Share of Equity Method Net Carrying Basis Losses Value Common stock $ 5,810,000 $ (5,810,000 ) $ - Preferred stock 18,397,000 (18,397,000 ) - $ 24,207,000 $ (24,207,000 ) $ - See Note 4 for more information and related party disclosure regarding Melt.
Accounting Guidance Issued but Not Adopted at September 30, 2024	Accounting Guidance Issued but Not Adopted at September 30, 2024 In October 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-06, Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures,

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2024
SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS	SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS Balance at January 1, 2024 $ 371,000 Change in expected credit losses (20,000 ) Write-offs, net of recoveries (70,000 ) Balance at September 30, 2024 $ 281,000
SCHEDULE OF ESTIMATED FAIR VALUE	The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE September 30, 2024 December 31, 2023 Carrying Value Fair Value Carrying Value Fair Value 2026 Notes $ 73,804,000 $ 76,830,000 $ 73,218,000 $ 70,260,000 2027 Notes $ 37,950,000 $ 43,084,000 $ 37,413,000 $ 40,363,000 Oaktree Loan $ 74,303,000 $ 78,663,000 $ 72,541,000 $ 76,627,000
SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK	The following table shows the computation of basic and diluted net loss per share of common stock: SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Numerator – net loss $ (4,220,000 ) $ (4,391,000 ) $ (24,258,000 ) $ (15,263,000 ) Denominator – weighted average number of shares outstanding, basic and diluted 35,702,200 34,255,197 35,597,409 31,689,947 Net loss per share, basic and diluted $ (0.12 ) $ (0.13 ) $ (0.68 ) $ (0.48 )
Melt Pharmaceuticals, Inc. [Member]
SCHEDULE OF INVESTMENT	The following table summarizes the Company’s investments in Melt as of September 30, 2024: SCHEDULE OF INVESTMENT Cost Share of Equity Method Net Carrying Basis Losses Value Common stock $ 5,810,000 $ (5,810,000 ) $ - Preferred stock 18,397,000 (18,397,000 ) - $ 24,207,000 $ (24,207,000 ) $ -

REVENUES (Tables)

REVENUES (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
SCHEDULE OF DISAGGREGATED REVENUE	Revenue disaggregated by revenue source consisted of the following: SCHEDULE OF DISAGGREGATED REVENUE For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Product sales, net $ 49,019,000 $ 31,809,000 $ 132,398,000 $ 81,804,000 Other revenues 238,000 2,456,000 385,000 12,034,000 Total revenues $ 49,257,000 $ 34,265,000 $ 132,783,000 $ 93,838,000

INVESTMENT IN, AND NOTE RECEI_2

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF CONDENSED INCOME STATEMENT	The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT For the Nine Months Ended September 30, 2024 2023 Revenues, net $ - $ - Loss from operations $ (11,334,000 ) $ (3,663,000 ) Net loss $ (10,942,000 ) $ (5,407,000 )
SCHEDULE OF CONDENSED BALANCE SHEET	The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET At September 30, At December 31, 2024 2023 Current assets $ 7,366,000 $ 13,404,000 Total assets $ 7,366,000 $ 13,404,000 Total liabilities $ 5,242,000 $ 3,922,000 Total stockholders’ equity 2,124,000 9,482,000 Total liabilities and stockholders’ equity $ 7,366,000 $ 13,404,000

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories was as follows: SCHEDULE OF INVENTORIES At September 30, 2024 At December 31, 2023 Raw materials $ 5,306,000 $ 5,477,000 Work in progress 176,000 54,000 Finished goods 4,674,000 5,336,000 Total inventories $ 10,156,000 $ 10,867,000

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS At September 30, 2024 At December 31, 2023 Prepaid insurance $ 1,639,000 $ 1,241,000 Prepaid computer software licenses and related expenses 619,000 1,613,000 Prefunded co-pay assistance 4,514,000 - Other prepaid expenses 1,749,000 906,000 Receivable due from Melt 228,000 228,000 Prepaid FY 2024 Prescription Drug User (“PDUFA”) fees - 3,438,000 Deferred Oaktree Loan commitment fee 372,000 409,000 Deposits and other current assets 1,450,000 1,753,000 Total prepaid expenses and other current assets $ 10,571,000 $ 9,588,000

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT At September 30, 2024 At December 31, 2023 Property, plant and equipment: Computer hardware $ 1,477,000 $ 1,322,000 Furniture and equipment 965,000 936,000 Lab and pharmacy equipment 5,304,000 4,564,000 Leasehold improvements 6,899,000 6,771,000 Property, plant and equipment, gross 14,645,000 13,593,000 Accumulated depreciation (11,020,000 ) (10,072,000 ) Property, plant and equipment, net $ 3,625,000 $ 3,521,000

CAPITALIZED SOFTWARE COSTS (Tab

CAPITALIZED SOFTWARE COSTS (Tables)	9 Months Ended
	Sep. 30, 2024
Capitalized Software Costs
SCHEDULE OF CAPITALIZED SOFTWARE COSTS	Capitalized software costs consisted of the following: SCHEDULE OF CAPITALIZED SOFTWARE COSTS At September 30, 2024 At December 31, 2023 Capitalized software costs: Capitalized internal-use software development costs $ 3,366,000 $ 2,780,000 Acquired third-party software license for internal-use 205,000 159,000 Total gross capitalized software for internal-use 3,571,000 2,939,000 Accumulated amortization (1,702,000 ) (1,268,000 ) Capitalized internal-use software in process - 467,000 Total capitalized software costs net $ 1,869,000 $ 2,138,000

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The Company’s intangible assets at September 30, 2024 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS Amortization Periods (in years) Cost Accumulated Amortization Net Carrying Value Patents 7 19 $ 610,000 $ (207,000 ) $ 403,000 Licenses 7 20 50,000 (36,000 ) 14,000 Trademarks Indefinite 226,000 - 226,000 Acquired NDAs 4 15 207,398,000 (18,899,000 ) 188,499,000 Customer relationships 3 15 596,000 (539,000 ) 57,000 Trade name 5 75,000 (7,000 ) 68,000 Non-competition clause 3 4 50,000 (50,000 ) - State pharmacy licenses 25 8,000 (3,000 ) 5,000 $ 209,013,000 $ (19,741,000 ) $ 189,272,000
SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS	Amortization expense for intangible assets was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Patents $ 19,000 $ 22,000 $ 47,000 $ 65,000 Licenses 34,000 2,000 34,000 7,000 Acquired NDAs 2,547,000 2,551,000 7,606,000 7,526,000 Customer relationships 3,000 9,000 19,000 36,000 Trade name 1,000 - 1,000 - State pharmacy licenses 1,000 - 1,000 - Amortization expense of intangible assets $ 2,605,000 $ 2,584,000 $ 7,708,000 $ 7,634,000
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE	Estimated future amortization expenses for the Company’s intangible assets at September 30, 2024 was as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE Remainder of 2024 $ 4,025,000 2025 16,630,000 2026 16,630,000 2027 16,281,000 2028 15,933,000 Thereafter 119,547,000 Intangible assets $ 189,046,000

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES At September 30, At December 31, 2024 2023 Accounts payable $ 23,202,000 $ 21,424,000 Accrued insurance premium 21,000 873,000 Other accrued payments 106,000 306,000 Accrued interest (see Note 11) 1,948,000 1,978,000 Accrued exit fee for Oaktree Loan (see Note 11) 2,713,000 2,713,000 Total accounts payable and accrued expenses $ 27,990,000 $ 27,294,000 Less: current portion (25,277,000 ) (24,581,000 ) Non-current total accrued expenses $ 2,713,000 $ 2,713,000

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
SCHEDULE OF LONG TERM DEBT	A summary of the Company’s debt is described as follows: SCHEDULE OF LONG TERM DEBT At September 30, At December 31, 2024 2023 8.625 April 2026 $ 75,000,000 $ 75,000,000 11.875 December 2027 40,250,000 40,250,000 Oaktree Loan due January 2026 77,500,000 77,500,000 Notes payable gross 192,750,000 192,750,000 Less: Unamortized debt issuance costs, net of premium (6,693,000 ) (9,578,000 ) Notes payable net $ 186,057,000 $ 183,172,000
SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES	At September 30, 2024, future minimum payments under the Company’s debt were as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES Amount Remainder of 2024 $ 5,166,000 2025 20,560,000 2026 159,895,000 2027 45,030,000 Total minimum payments 230,651,000 Less: amount representing interest payments (37,901,000 ) Notes payable, gross principal amount due 192,750,000 Less: unamortized debt issuance costs, net of premium (6,693,000 ) Notes payable, net of unamortized debt issuance costs $ 186,057,000

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES	Future lease payments under operating leases as of September 30, 2024 were as follows : SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES Operating Leases Remainder of 2024 $ 329,000 2025 1,386,000 2026 1,767,000 2027 1,641,000 2028 1,342,000 Thereafter 7,971,000 Total minimum lease payments 14,436,000 Less: amount representing interest payments (4,429,000 ) Total operating lease obligations 10,007,000 Less: current portion, operating lease obligations (507,000 ) Operating lease obligations, net of current portion $ 9,500,000

STOCKHOLDERS_ EQUITY AND STOC_2

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SCHEDULE OF STOCK OPTION PLAN ACTIVITY	A summary of stock option activity under the Plans for the nine months ended September 30, 2024 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Options outstanding – January 1, 2024 2,711,317 $ 6.25 Options granted 140,000 $ 14.72 Options exercised (270,865 ) $ 7.12 Options cancelled/forfeited (100,063 ) $ 13.56 Options outstanding – September 30, 2024 2,480,389 $ 6.33 3.44 $ 95,807,000 Options exercisable 2,218,148 $ 5.50 2.80 $ 87,536,000 Options vested and expected to vest 2,444,924 $ 6.21 3.36 $ 94,733,000
SCHEDULE OF FAIR VALUE ASSUMPTIONS	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2024 Weighted-average fair value of options granted $ 9.64 Expected terms (in years) 6.11 Expected volatility 67.78 72.95 % Risk-free interest rate 3.72 4.48 % Dividend yield -
SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable at September 30, 2024: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 1.47 1.70 31,942 2.96 $ 1.68 31,942 $ 1.68 $ 1.73 250,000 3.25 $ 1.73 250,000 $ 1.73 $ 2.23 270,000 2.34 $ 2.23 270,000 $ 2.23 $ 2.40 2.60 14,068 2.33 $ 2.57 14,068 $ 2.57 $ 3.95 308,500 1.50 $ 3.95 308,500 $ 3.95 $ 4.49 5.72 92,300 4.86 $ 5.53 92,300 $ 5.53 $ 6.30 285,000 4.39 $ 6.30 285,000 $ 6.30 $ 6.75 7.26 46,036 7.76 $ 6.85 18,162 $ 6.77 $ 7.30 274,500 5.26 $ 7.30 274,500 $ 7.30 $ 7.60 39.63 908,043 3.31 $ 9.63 673,676 $ 8.04 $ 1.47 39.63 2,480,389 3.44 $ 6.33 2,218,148 $ 5.50
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY	A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2024 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY Number of Shares Weighted Average Grant Date Fair Value RSUs unvested - January 1, 2024 363,029 $ 9.23 RSUs granted 319,081 23.93 RSUs vested (312,674 ) 9.84 RSUs cancelled/forfeited (6,250 ) 8.10 RSUs unvested - September 30, 2024 363,186 $ 21.63
SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY	A summary of the Company’s PSU activity and related information for the nine months ended September 30, 2024 is as follows: SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY Number of Shares Weighted Average Grant Date Fair Value PSUs unvested – January 1, 2024 1,567,913 $ 18.56 PSUs granted - PSUs vested - PSUs cancelled/forfeited - PSUs unvested – September 30, 2024 1,567,913 $ 18.56
SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS	The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Employees - selling, general and administrative $ 3,728,000 $ 3,784,000 $ 10,832,000 $ 9,719,000 Employees - research and development 422,000 475,000 1,300,000 1,224,000 Directors - selling, general and administrative 199,000 200,000 601,000 528,000 Consultants - selling, general and administrative 36,000 17,000 92,000 50,000 Total $ 4,385,000 $ 4,476,000 $ 12,825,000 $ 11,521,000

SEGMENTS AND CONCENTRATIONS (Ta

SEGMENTS AND CONCENTRATIONS (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT NET REVENUES	Segment net revenues, segment operating expenses and segment contribution information consisted of the following: SCHEDULE OF SEGMENT NET REVENUES Branded ImprimisRx Consolidated Three Months Ended September 30, 2024 Branded ImprimisRx Consolidated Product sales, net $ 28,314,000 $ 20,705,000 $ 49,019,000 Other revenues 238,000 - 238,000 Total revenues 28,552,000 20,705,000 49,257,000 Cost of sales (5,169,000 ) (6,849,000 ) (12,018,000 ) Gross profit 23,383,000 13,856,000 37,239,000 Operating expenses: Selling, general and administrative 14,038,000 5,427,000 19,465,000 Research and development 212,000 84,000 296,000 Segment contribution $ 9,133,000 $ 8,345,000 17,478,000 Corporate 14,180,000 Research and development 1,977,000 Income from operations $ 1,321,000 Branded ImprimisRx Consolidated Three Months Ended September 30, 2023 Branded ImprimisRx Consolidated Product sales, net $ 12,040,000 $ 19,769,000 $ 31,809,000 Other revenues 2,456,000 - 2,456,000 Total revenues 14,496,000 19,769,000 34,265,000 Cost of sales (3,335,000 ) (6,732,000 ) (10,067,000 ) Gross profit 11,161,000 13,037,000 24,198,000 Operating expenses: Selling, general and administrative 1,930,000 7,703,000 9,633,000 Research and development 37,000 159,000 196,000 Segment contribution $ 9,194,000 $ 5,175,000 14,369,000 Corporate 11,400,000 Research and development 1,225,000 Income from operations $ 1,744,000 Branded ImprimisRx Consolidated Nine Months Ended September 30, 2024 Branded ImprimisRx Consolidated Product sales, net $ 69,395,000 $ 63,003,000 $ 132,398,000 Other revenues 385,000 - 385,000 Total revenues 69,780,000 63,003,000 132,783,000 Cost of sales (14,406,000 ) (20,704,000 ) (35,110,000 ) Gross profit 55,374,000 42,299,000 97,673,000 Operating expenses: Selling, general and administrative 36,034,000 17,364,000 53,398,000 Research and development 321,000 261,000 582,000 Segment contribution $ 19,019,000 $ 24,674,000 43,693,000 Corporate 40,877,000 Research and development 6,893,000 Loss from operations $ (4,077,000 ) Branded ImprimisRx Consolidated Nine Months Ended September 30, 2023 Branded ImprimisRx Consolidated Product sales, net $ 21,829,000 $ 59,975,000 $ 81,804,000 Other revenues 12,034,000 - 12,034,000 Total revenues 33,863,000 59,975,000 93,838,000 Cost of sales (8,396,000 ) (19,942,000 ) (28,338,000 ) Gross profit 25,467,000 40,033,000 65,500,000 Operating expenses: Selling, general and administrative 4,797,000 23,334,000 28,131,000 Research and development 37,000 560,000 597,000 Segment contribution $ 20,633,000 $ 16,139,000 36,772,000 Corporate 28,747,000 Research and development 2,719,000 Income from operations $ 5,306,000
SCHEDULE OF REVENUES BY SEGMENT	Revenues by segment are further described as follows: SCHEDULE OF REVENUES BY SEGMENT For the Three Months Ended For the Nine Months Ended September 30, September 30, 2024 2023 2024 2023 IHEEZO $ 12,882,000 26 % $ 5,927,000 17 % $ 26,498,000 20 % $ 10,073,000 11 % VEVYE 5,186,000 11 % - - % 12,099,000 9 % - - % Other products (Anterior Segment) 10,256,000 21 % 6,605,000 19 % 30,808,000 23 % 13,205,000 14 % Other revenue, net 228,000 0 % 1,964,000 6 % 375,000 0 % 10,585,000 11 % Branded revenue, net 28,552,000 58 % 14,496,000 42 % 69,780,000 53 % 33,863,000 36 % ImprimisRx revenue, net 20,705,000 42 % 19,769,000 58 % 63,003,000 47 % 59,975,000 64 % Total revenues, net $ 49,257,000 100 % $ 34,265,000 100 % $ 132,783,000 100 % $ 93,838,000 100 %

DESCRIPTION OF BUSINESS AND B_2

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Consolidation basis description	(i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights

SCHEDULE OF ACCOUNTS RECEIVABLE

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 371,000
Change in expected credit losses	(20,000)
Write-offs, net of recoveries	(70,000)
Ending balance	$ 281,000

SCHEDULE OF ESTIMATED FAIR VALU

SCHEDULE OF ESTIMATED FAIR VALUE (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Carrying value	$ 192,750,000	$ 192,750,000
Oaktree Loan [Member]
Platform Operator, Crypto Asset [Line Items]
Carrying value	77,500,000	77,500,000
Fair Value, Inputs, Level 1 [Member] | 2026 Notes [Member]
Platform Operator, Crypto Asset [Line Items]
Carrying value	73,804,000	73,218,000
Fair value	76,830,000	70,260,000
Fair Value, Inputs, Level 1 [Member] | 2027 Notes [Member]
Platform Operator, Crypto Asset [Line Items]
Carrying value	37,950,000	37,413,000
Fair value	43,084,000	40,363,000
Fair Value, Inputs, Level 2 [Member] | Oaktree Loan [Member]
Platform Operator, Crypto Asset [Line Items]
Carrying value	74,303,000	72,541,000
Fair value	$ 78,663,000	$ 76,627,000

SCHEDULE OF BASIC NET LOSS PER

SCHEDULE OF BASIC NET LOSS PER SHARE OF COMMON STOCK (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Numerator – net loss	$ (4,220,000)	$ (4,391,000)	$ (24,258,000)	$ (15,263,000)
Denominator - weighted average number of shares outstanding, basic	35,702,200	34,255,197	35,597,409	31,689,947
Denominator - weighted average number of shares outstanding, diluted	35,702,200	34,255,197	35,597,409	31,689,947
Net loss per share, basic	$ (0.12)	$ (0.13)	$ (0.68)	$ (0.48)
Net loss per share, diluted	$ (0.12)	$ (0.13)	$ (0.68)	$ (0.48)

SCHEDULE OF INVESTMENT (Details

SCHEDULE OF INVESTMENT (Details) - Melt Pharmaceuticals, Inc. [Member]	9 Months Ended
	Sep. 30, 2024 USD ($)
Schedule of Investments [Line Items]
Cost basis	$ 24,207,000
Share of Equity Method Losses	(24,207,000)
Net Carrying Value
Common Stock [Member]
Schedule of Investments [Line Items]
Cost basis	5,810,000
Share of Equity Method Losses	(5,810,000)
Net Carrying Value
Preferred Stock [Member]
Schedule of Investments [Line Items]
Cost basis	18,397,000
Share of Equity Method Losses	(18,397,000)
Net Carrying Value

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accounts receivable		$ 53,734,000		$ 53,734,000
Accounts receivable, net of allowances for credit losses		281,000		281,000
Loss on sale of investments			$ (1,348,000)	$ 3,171,000	$ (2,676,000)
Effective income tax rate				(2.95%)	(8.81%)
Federal income tax rate				21%	21%
Unrecognized tax benefits		$ 0		$ 0		$ 0
Melt Pharmaceuticals, Inc. [Member]
Ownership percentage		46%		46%
Melt Pharmaceuticals, Inc. [Member] | Common Stock [Member]
Investment owned balance shares		3,500,000		3,500,000
Melt Pharmaceuticals, Inc. [Member] | Preferred Stock [Member]
Investment owned balance shares		2,334,256		2,334,256
Restricted Stock Units (RSUs) [Member]
Number of shares vested				$ 195,696	$ 244,352
Stock Options, Unvested RSUs And Unvested PSUs [Member]
Stock excluded in calculation of diluted net loss per common share				4,411,488	4,588,982
Eton Pharmaceuticals, Inc. [Member]
Investment owned at fair value						$ 8,681,000
Trading and commissions expenses	$ 436,000
Net proceeds from issuance of shares	$ 5,510,000
Eton Pharmaceuticals, Inc. [Member] | Common Stock [Member]
Gross price	$ 3

SCHEDULE OF DISAGGREGATED REVEN

SCHEDULE OF DISAGGREGATED REVENUE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total revenues	$ 49,257,000	$ 34,265,000	$ 132,783,000	$ 93,838,000
Product Sales, Net [Member]
Disaggregation of Revenue [Line Items]
Total revenues	49,019,000	31,809,000	132,398,000	81,804,000
Other Revenues [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 238,000	$ 2,456,000	$ 385,000	$ 12,034,000

REVENUES (Details Narrative)

REVENUES (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Deferred revenue and customer deposits	$ 137,000	$ 75,000

SCHEDULE OF CONDENSED INCOME ST

SCHEDULE OF CONDENSED INCOME STATEMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues, net	$ 49,257,000	$ 34,265,000	$ 132,783,000	$ 93,838,000
Loss from operations	1,321,000	1,744,000	(4,077,000)	5,306,000
Net loss	$ (4,220,000)	$ (4,391,000)	(24,258,000)	(15,263,000)
Melt Pharmaceuticals, Inc. [Member]
Revenues, net
Loss from operations			(11,334,000)	(3,663,000)
Net loss			$ (10,942,000)	$ (5,407,000)

SCHEDULE OF CONDENSED BALANCE S

SCHEDULE OF CONDENSED BALANCE SHEET (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets	$ 147,062,000	$ 139,482,000
Total assets	351,539,000	312,164,000
Total liabilities	293,918,000	241,753,000
Total stockholders’ equity	57,976,000	70,766,000
Total liabilities and stockholders’ equity	351,539,000	312,164,000
Melt Pharmaceuticals, Inc. [Member]
Current assets	7,366,000	13,404,000
Total assets	7,366,000	13,404,000
Total liabilities	5,242,000	3,922,000
Total stockholders’ equity	2,124,000	9,482,000
Total liabilities and stockholders’ equity	$ 7,366,000	$ 13,404,000

INVESTMENT IN, AND NOTE RECEI_3

INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative) - Melt Pharmaceuticals, Inc. [Member] - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Mar. 31, 2024	Feb. 28, 2019	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2024	Dec. 31, 2023
Reimbursable expenses			$ 0	$ 89,000
Due from related party					$ 228,000	$ 228,000
Series B Preferred Stock [Member]
Gross proceeds from stock financing	$ 23,900,000
Management Services Agreement [Member]
Administrative fees expense		$ 10,000

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 5,306,000	$ 5,477,000
Work in progress	176,000	54,000
Finished goods	4,674,000	5,336,000
Total inventories	$ 10,156,000	$ 10,867,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 1,639,000	$ 1,241,000
Prepaid computer software licenses and related expenses	619,000	1,613,000
Prefunded co-pay assistance	4,514,000
Other prepaid expenses	1,749,000	906,000
Receivable due from Melt	228,000	228,000
Prepaid FY 2024 Prescription Drug User (“PDUFA”) fees		3,438,000
Deferred Oaktree Loan commitment fee	372,000	409,000
Deposits and other current assets	1,450,000	1,753,000
Total prepaid expenses and other current assets	$ 10,571,000	$ 9,588,000

SCHEDULE OF PROPERTY, PLANT AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Computer hardware	$ 1,477,000	$ 1,322,000
Furniture and equipment	965,000	936,000
Lab and pharmacy equipment	5,304,000	4,564,000
Leasehold improvements	6,899,000	6,771,000
Property, plant and equipment, gross	14,645,000	13,593,000
Accumulated depreciation	(11,020,000)	(10,072,000)
Property, plant and equipment, net	$ 3,625,000	$ 3,521,000

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 351,000	$ 290,000	$ 948,000	$ 743,000

SCHEDULE OF CAPITALIZED SOFTWAR

SCHEDULE OF CAPITALIZED SOFTWARE COSTS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	$ 3,571,000	$ 2,939,000
Accumulated amortization	(1,702,000)	(1,268,000)
Capitalized internal-use software in process		467,000
Total capitalized software costs net	1,869,000	2,138,000
Capitalized Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	3,366,000	2,780,000
Third Party Software License [Member]
Finite-Lived Intangible Assets [Line Items]
Total gross capitalized software for internal-use	$ 205,000	$ 159,000

CAPITALIZED SOFTWARE COSTS (Det

CAPITALIZED SOFTWARE COSTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Capitalized Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expenses	$ 146,000	$ 115,000	$ 434,000	$ 352,000

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	$ 209,013,000
Intangible assets, Accumulated amortization	(19,741,000)
Intangible assets, Net Carrying value	189,272,000	$ 159,906,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	610,000
Intangible assets, Accumulated amortization	(207,000)
Intangible assets, Net Carrying value	403,000
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	50,000
Intangible assets, Accumulated amortization	(36,000)
Intangible assets, Net Carrying value	14,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	226,000
Intangible assets, Accumulated amortization
Intangible assets, Net Carrying value	$ 226,000
Useful life, description	Indefinite
New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	$ 207,398,000
Intangible assets, Accumulated amortization	(18,899,000)
Intangible assets, Net Carrying value	188,499,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	596,000
Intangible assets, Accumulated amortization	(539,000)
Intangible assets, Net Carrying value	$ 57,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	5 years
Intangible assets, Cost	$ 75,000
Intangible assets, Accumulated amortization	(7,000)
Intangible assets, Net Carrying value	68,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Cost	50,000
Intangible assets, Accumulated amortization	(50,000)
Intangible assets, Net Carrying value
State Pharmacy Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	25 years
Intangible assets, Cost	$ 8,000
Intangible assets, Accumulated amortization	(3,000)
Intangible assets, Net Carrying value	$ 5,000
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	7 years
Minimum [Member] | Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	7 years
Minimum [Member] | New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	4 years
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	3 years
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	3 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	19 years
Maximum [Member] | Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	20 years
Maximum [Member] | New Drug Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	15 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	15 years
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Useful life	4 years

SCHEDULE OF AMORTIZATION EXPENS

SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	$ 2,605,000	$ 2,584,000	$ 7,708,000	$ 7,634,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	19,000	22,000	47,000	65,000
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	34,000	2,000	34,000	7,000
Acquired NDAs [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	2,547,000	2,551,000	7,606,000	7,526,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	3,000	9,000	19,000	36,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	1,000		1,000
State Pharmacy Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	$ 1,000		$ 1,000

SCHEDULE OF ESTIMATED FUTURE AM

SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2024	$ 4,025,000
2025	16,630,000
2026	16,630,000
2027	16,281,000
2028	15,933,000
Thereafter	119,547,000
Intangible assets	$ 189,046,000

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire intangible assets			$ 74,000
Carrying value of goodwill	$ 0	$ 0	$ 0	$ 0
Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire intangible assets	$ 37,000,000

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable	$ 23,202,000	$ 21,424,000
Accrued insurance premium	21,000	873,000
Other accrued payments	106,000	306,000
Accrued interest (see Note 11)	1,948,000	1,978,000
Accrued exit fee for Oaktree Loan (see Note 11)	2,713,000	2,713,000
Total accounts payable and accrued expenses	27,990,000	27,294,000
Less: current portion	(25,277,000)	(24,581,000)
Non-current total accrued expenses	$ 2,713,000	$ 2,713,000

SCHEDULE OF LONG TERM DEBT (Det

SCHEDULE OF LONG TERM DEBT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Notes payable gross	$ 192,750,000	$ 192,750,000
Less: Unamortized debt issuance costs, net of premium	(6,693,000)	(9,578,000)
Notes payable net	186,057,000	183,172,000
8.625% Senior Notes Due 2026 [Member]
Short-Term Debt [Line Items]
Notes payable gross	75,000,000	75,000,000
11.875% Senior Notes Due 2027 [Member]
Short-Term Debt [Line Items]
Notes payable gross	40,250,000	40,250,000
Oaktree Loan [Member]
Short-Term Debt [Line Items]
Notes payable gross	$ 77,500,000	$ 77,500,000

SCHEDULE OF LONG TERM DEBT (D_2

SCHEDULE OF LONG TERM DEBT (Details) (Parenthetical)	2 Months Ended	6 Months Ended	9 Months Ended
	Jan. 31, 2023	Sep. 30, 2021	Sep. 30, 2024
8.625% Senior Notes Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate, during period		8.625%	8.625%
Maturity period		April 2026	April 2026
11.875% Senior Notes Due 2027 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate, during period	11.875%		11.875%
Maturity period	December 2027		December 2027
Oaktree Loan [Member]
Debt Instrument [Line Items]
Maturity period			January 2026

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Remainder of 2024	$ 5,166,000
2025	20,560,000
2026	159,895,000
2027	45,030,000
Total minimum payments	230,651,000
Less: amount representing interest payments	(37,901,000)
Notes payable, gross principal amount due	192,750,000	$ 192,750,000
Less: unamortized debt issuance costs, net of premium	(6,693,000)	(9,578,000)
Notes payable, net of unamortized debt issuance costs	$ 186,057,000	$ 183,172,000

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)		1 Months Ended		2 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Mar. 27, 2024	Jul. 31, 2023	Mar. 31, 2023	Jan. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2021	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jul. 01, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Amortization of financing costs and discount								$ 2,985,000	$ 2,568,000
Effective interest rate					11.03%	10.78%		11.17%	10.91%
Oaktree Loan [Member]
Debt Instrument [Line Items]
Interest expense other than long term debt					$ 3,026,000	$ 2,995,000		$ 8,923,000	$ 5,660,000
Amortization of financing costs and discount					$ 656,000	567,000		$ 1,861,000	1,093,000
Exit fee percentage					3.50%			3.50%
Accrued exit fee liability					$ 2,713,000			$ 2,713,000		$ 2,713,000
Maturity period								January 2026
11.875% Senior Notes Due 2027 [Member]
Debt Instrument [Line Items]
Interest expense other than long term debt					1,376,000	1,375,000		$ 4,121,000	4,141,000
Amortization of financing costs and discount					$ 181,000	180,000		$ 537,000	556,000
Face amount				$ 40,250,000
Interest rate				11.875%	11.875%			11.875%
Maturity period				December 2027				December 2027
8.625% Senior Notes Due 2026 [Member]
Debt Instrument [Line Items]
Interest expense other than long term debt					$ 1,814,000	1,814,000		$ 5,438,000	5,436,000
Amortization of financing costs and discount					$ 197,000	$ 197,000		$ 587,000	$ 585,000
Face amount							$ 75,000,000
Interest rate					8.625%		8.625%	8.625%
Maturity period							April 2026	April 2026
Oaktree Loan [Member] | Oaktree Fund Administration LLC [Member]
Debt Instrument [Line Items]
Principal amount drawn		$ 12,500,000	$ 65,000,000
Oaktree Loan [Member] | Oaktree Fund Administration LLC [Member] | Tranche B [Member]
Debt Instrument [Line Items]
Loan maximum borrowing capacity	$ 30,000,000										$ 35,000,000
Commitment fee percentage for undrawn amount	2%
Oaktree Loan [Member] | Oaktree Fund Administration LLC [Member] | Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Loan maximum borrowing capacity			$ 100,000,000
Oaktree Credit Agreement Amendment [Member]
Debt Instrument [Line Items]
Loan maximum borrowing capacity											$ 112,500,000	$ 100,000,000

SCHEDULE OF FUTURE LEASE PAYMEN

SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Remainder of 2024	$ 329,000
2025	1,386,000
2026	1,767,000
2027	1,641,000
2028	1,342,000
Thereafter	7,971,000
Total minimum lease payments	14,436,000
Less: amount representing interest payments	(4,429,000)
Total operating lease obligations	10,007,000
Less: current portion, operating lease obligations	(507,000)	$ (806,000)
Operating lease obligations, net of current portion	$ 9,500,000	$ 6,524,000

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended							3 Months Ended		9 Months Ended
	Mar. 31, 2024 USD ($) ft²	Jan. 31, 2024 ft²	Sep. 30, 2022 ft²	Jan. 31, 2022 ft²	May 31, 2021 ft²	Jul. 31, 2020 ft²	Jan. 31, 2020 ft²	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Weighted average incremental borrowing rate								7.85%		7.85%
Weighted average remaining lease term								10 years 4 months 24 days		10 years 4 months 24 days
Cash paid for amounts included for operating lease liabilities | $								$ 327,000	$ 310,000	$ 972,000	$ 921,000
Selling, General and Administrative Expenses [Member]
Operating lease expense | $								$ 414,000	$ 309,000	$ 1,053,000	$ 926,000
Carlsbad [Member]
Lease area				5,789
Lease expiration date, description				March 2025
Ledgewood [Member]
Lease area						38,153
Lease expiration date, description						July 2027
Ledgewood [Member] | Lease Amendment [Member]
Lease expiration date, description					July 2027
Area of land		2,861			8,900	1,400
Nashville [Member]
Lease area	17,625		11,552				5,500
Lease expiration date, description			September 2027				December 2024
Lease, extension description							option to extend the term for two additional five-year periods
Lease not yet commenced, term	7 years
Lease not yet commenced, extension description	option to extend the term for two additional five-year periods
Operating lease assets liability | $	$ 2,853,000
Minimum [Member] | Office and Laboratory Space [Member]
Lease term								1 year		1 year
Maximum [Member] | Office and Laboratory Space [Member]
Lease term								7 years		7 years

SCHEDULE OF STOCK OPTION PLAN A

SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details) - Stock Option Plan [Member]	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, outstanding, beginning balance | shares	2,711,317
Weighted average exercise price, outstanding, beginning balance | $ / shares	$ 6.25
Number of shares, options granted | shares	140,000
Weighted average exercise price, options granted | $ / shares	$ 14.72
Number of shares, options exercised | shares	(270,865)
Weighted average exercise price, options exercised | $ / shares	$ 7.12
Number of shares, options cancelled/forfeited | shares	(100,063)
Weighted average exercise price, options cancelled/forfeited | $ / shares	$ 13.56
Number of shares, outstanding, ending balance | shares	2,480,389
Weighted average exercise price, outstanding, ending balance | $ / shares	$ 6.33
Weighted average. remaining contractual life, options outstanding	3 years 5 months 8 days
Aggregate intrinsic value, options outstanding | $	$ 95,807,000
Number of shares, options exercisable | shares	2,218,148
Weighted average exercise price, options exercisable | $ / shares	$ 5.50
Weighted average. remaining contractual life, options exercisable	2 years 9 months 18 days
Aggregate intrinsic value, options exercisable | $	$ 87,536,000
Number of shares, options vested and expected to vest | shares	2,444,924
Weighted average exercise price, options vested and expected to vest | $ / shares	$ 6.21
Weighted average. remaining contractual life, options vested and expected to vest	3 years 4 months 9 days
Aggregate intrinsic value, options exercisable | $	$ 94,733,000

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - Share-Based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average fair value of options granted	$ 9.64
Expected terms (in years)	6 years 1 month 9 days
Expected volatility minimum	67.78%
Expected volatility maximum	72.95%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	3.72%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	4.48%
Dividend yield

SCHEDULE OF STOCK OPTION OUTSTA

SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1.47
Range of Exercise Prices, maximum	$ 39.63
Number of Options Outstanding | shares	2,480,389
Weighted Average Remaining Contractual Life in Years	3 years 5 months 8 days
Weighted Average Exercise Price, Outstanding	$ 6.33
Number of Options Exercisable | shares	2,218,148
Weighted Average Exercise Price, Exercisable	$ 5.50
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	1.47
Range of Exercise Prices, maximum	$ 1.70
Number of Options Outstanding | shares	31,942
Weighted Average Remaining Contractual Life in Years	2 years 11 months 15 days
Weighted Average Exercise Price, Outstanding	$ 1.68
Number of Options Exercisable | shares	31,942
Weighted Average Exercise Price, Exercisable	$ 1.68
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 1.73
Number of Options Outstanding | shares	250,000
Weighted Average Remaining Contractual Life in Years	3 years 3 months
Weighted Average Exercise Price, Outstanding	$ 1.73
Number of Options Exercisable | shares	250,000
Weighted Average Exercise Price, Exercisable	$ 1.73
Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 2.23
Number of Options Outstanding | shares	270,000
Weighted Average Remaining Contractual Life in Years	2 years 4 months 2 days
Weighted Average Exercise Price, Outstanding	$ 2.23
Number of Options Exercisable | shares	270,000
Weighted Average Exercise Price, Exercisable	$ 2.23
Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	2.40
Range of Exercise Prices, maximum	$ 2.60
Number of Options Outstanding | shares	14,068
Weighted Average Remaining Contractual Life in Years	2 years 3 months 29 days
Weighted Average Exercise Price, Outstanding	$ 2.57
Number of Options Exercisable | shares	14,068
Weighted Average Exercise Price, Exercisable	$ 2.57
Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 3.95
Number of Options Outstanding | shares	308,500
Weighted Average Remaining Contractual Life in Years	1 year 6 months
Weighted Average Exercise Price, Outstanding	$ 3.95
Number of Options Exercisable | shares	308,500
Weighted Average Exercise Price, Exercisable	$ 3.95
Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	4.49
Range of Exercise Prices, maximum	$ 5.72
Number of Options Outstanding | shares	92,300
Weighted Average Remaining Contractual Life in Years	4 years 10 months 9 days
Weighted Average Exercise Price, Outstanding	$ 5.53
Number of Options Exercisable | shares	92,300
Weighted Average Exercise Price, Exercisable	$ 5.53
Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 6.30
Number of Options Outstanding | shares	285,000
Weighted Average Remaining Contractual Life in Years	4 years 4 months 20 days
Weighted Average Exercise Price, Outstanding	$ 6.30
Number of Options Exercisable | shares	285,000
Weighted Average Exercise Price, Exercisable	$ 6.30
Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	6.75
Range of Exercise Prices, maximum	$ 7.26
Number of Options Outstanding | shares	46,036
Weighted Average Remaining Contractual Life in Years	7 years 9 months 3 days
Weighted Average Exercise Price, Outstanding	$ 6.85
Number of Options Exercisable | shares	18,162
Weighted Average Exercise Price, Exercisable	$ 6.77
Range Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, maximum	$ 7.30
Number of Options Outstanding | shares	274,500
Weighted Average Remaining Contractual Life in Years	5 years 3 months 3 days
Weighted Average Exercise Price, Outstanding	$ 7.30
Number of Options Exercisable | shares	274,500
Weighted Average Exercise Price, Exercisable	$ 7.30
Range Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	7.60
Range of Exercise Prices, maximum	$ 39.63
Number of Options Outstanding | shares	908,043
Weighted Average Remaining Contractual Life in Years	3 years 3 months 21 days
Weighted Average Exercise Price, Outstanding	$ 9.63
Number of Options Exercisable | shares	673,676
Weighted Average Exercise Price, Exercisable	$ 8.04

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, unvested, outstanding, beginning balance | shares	363,029
Weighted average grant date fair value, beginning balance | $ / shares	$ 9.23
Number of Shares, RSUs granted | shares	319,081
Weighted average grant date fair value, RSUs granted | $ / shares	$ 23.93
Number of Shares, RSUs vested | shares	(312,674)
Weighted average grant date fair value, RSUs vested | $ / shares	$ 9.84
Number of Shares, RSUs cancelled/forfeited | shares	(6,250)
Weighted average grant date fair value, RSUs cancelled/forfeited | $ / shares	$ 8.10
Number of Shares, unvested, outstanding, ending balance | shares	363,186
Weighted average grant date fair value, ending balance | $ / shares	$ 21.63

SCHEDULE OF PERFORMANCE STOCK U

SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY (Details) - Performance Shares [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, unvested, outstanding, beginning balance	1,567,913
Weighted average grant date fair value, beginning balance | $ / shares	$ 18.56
Number of Shares, PSUs granted
Number of Shares, PSUs vested
Number of Shares, PSUs cancelled/forfeited
Number of Shares, unvested, outstanding, ending balance	1,567,913
Weighted average grant date fair value, ending balance | $ / shares	$ 18.56

SCHEDULE OF STOCK BASED COMPENS

SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total	$ 4,385,000	$ 4,476,000	$ 12,825,000	$ 11,521,000
Employees [Member] | Selling, General and Administrative Expenses [Member]
Total	3,728,000	3,784,000	10,832,000	9,719,000
Employees [Member] | Research and Development Expense [Member]
Total	422,000	475,000	1,300,000	1,224,000
Director [Member] | Selling, General and Administrative Expenses [Member]
Total	199,000	200,000	601,000	528,000
Consultants [Member] | Selling, General and Administrative Expenses [Member]
Total	$ 36,000	$ 17,000	$ 92,000	$ 50,000

STOCKHOLDERS_ EQUITY AND STOC_3

STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from stock option exercised			$ 1,005,000	$ 355,000
Exercise price, minimum			$ 1.47
Exercise price, maximum			$ 39.63
Number of shares issued of common stock
Stock-based compensation	$ 4,385,000	$ 4,476,000	$ 12,825,000	11,521,000
2017 Incentive Stock and Awards Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares available for future issuances	53,344		53,344
Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Forfeiture factor rate			10%
Maximum [Member] | 2017 Incentive Stock and Awards Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized for issuance	6,000,000		6,000,000
Share-Based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Closing price of common stock price per share	$ 44.96		$ 44.96
Unrecognized compensation expense	$ 2,071,000		$ 2,071,000
Weighted-average period for recognition			2 years 9 months 29 days
Stock-based compensation	160,000	154,000	$ 416,000	617,000
Intrinsic value of options exercised			$ 6,651,000
Share-Based Payment Arrangement, Option [Member] | Employees and Consultant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting term description			The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of ten years. Vesting terms for options granted to employees during the nine months ended September 30, 2024 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted			319,081
Number of shares vested of common stock			312,674
Unrecognized compensation expense	7,324,000		$ 7,324,000
Weighted-average period for recognition			2 years
Stock-based compensation	587,000	374,000	$ 1,494,000	789,000
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares vested of common stock			50,000
Restricted Stock Units (RSUs) [Member] | Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares vested of common stock			3,872
Restricted Stock Units (RSUs) [Member] | Andrew R. Boll [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted			45,000
Restricted Stock Units (RSUs) [Member] | Mark L. Baum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted			150,000
Restricted Stock Units (RSUs) [Member] | John Saharek [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares vested of common stock			30,000
Performance Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted
Number of shares vested of common stock
Unrecognized compensation expense	7,277,000		$ 7,277,000
Weighted-average period for recognition			6 months 3 days
Stock-based compensation	$ 3,638,000	$ 3,948,000	$ 10,915,000	$ 10,115,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock		3,887,324	32,580	3,887,324
Proceeds from stock option exercised			$ 1,005,000
Options exercise price			39,237	10,000
Exercise price, minimum			$ 1.70
Exercise price, maximum			25.86
Exercise price per share	$ 1.70		$ 1.70
Number of shares issued of common stock
Common Stock [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock			44,860
Exercise price per share	8		$ 8
Common Stock [Member] | Share-Based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock			141,628
Options exercise price			141,628
Common Stock [Member] | Options Held [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options exercise price			90,000
Exercise price per share	$ 7.37		$ 7.37
Shares withheld for tax withholding obligation, shares			29,107
Payroll tax obligations, value			$ 1,205,000
Common Stock [Member] | Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued for services			3,667
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | Employees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares withheld for tax withholding obligation, shares			17,548
Payroll tax obligations, value			$ 187,000
Number of shares issued of common stock			32,452
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued of common stock			$ 57,517
Number of shares issued for services			34,008
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | Andrew R. Boll [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares withheld for tax withholding obligation, shares			18,480
Payroll tax obligations, value			$ 197,000
Number of shares issued of common stock			$ 26,520
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | Mark L. Baum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares withheld for tax withholding obligation, shares			59,836
Payroll tax obligations, value			$ 638,000
Number of shares issued of common stock			$ 90,164
Common Stock [Member] | Restricted Stock Units (RSUs) [Member] | John Saharek [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares withheld for tax withholding obligation, shares			12,616
Payroll tax obligations, value			$ 135,000
Number of shares issued of common stock			$ 17,384

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024
Loss Contingencies [Line Items]
Reduction in milestone amounts		$ 550,000		$ 550,000
Payment for milestone		4,450,000		4,450,000
Forecast [Member]
Loss Contingencies [Line Items]
Payment of minimum annual order amounts					$ 2,728,000
Asset Purchase, License and Related Agreements [Member]
Loss Contingencies [Line Items]
Royalty expenses	$ 730,000	220,000	$ 2,040,000	705,000
Upfront and milestone payments	0		0
Asset Purchase and License Agreements [Member]
Loss Contingencies [Line Items]
Royalty expenses	$ 453,000	300,000	$ 949,000	951,000
Sales and Marketing Agreements [Member]
Loss Contingencies [Line Items]
Description for commission payments			Under the terms of the sales and marketing agreements, the Company was generally required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts
Commission expenses		$ 0		$ 130,000
Sales and Marketing Agreements [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Commission payments percentage			10%
Sales and Marketing Agreements [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Commission payments percentage			14%

SCHEDULE OF SEGMENT NET REVENUE

SCHEDULE OF SEGMENT NET REVENUES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Total revenues	$ 49,257,000	$ 34,265,000	$ 132,783,000	$ 93,838,000
Cost of sales	(12,018,000)	(10,067,000)	(35,110,000)	(28,338,000)
Gross profit	37,239,000	24,198,000	97,673,000	65,500,000
Operating expenses:
Selling, general and administrative	33,645,000	21,033,000	94,275,000	56,878,000
Research and development	2,273,000	1,421,000	7,475,000	3,316,000
Operating expenses	35,918,000	22,454,000	101,750,000	60,194,000
Income from operations	1,321,000	1,744,000	(4,077,000)	5,306,000
Operating Segments [Member]
Operating expenses:
Selling, general and administrative	19,465,000	9,633,000	53,398,000	28,131,000
Research and development	296,000	196,000	582,000	597,000
Operating expenses	17,478,000	14,369,000	43,693,000	36,772,000
Product Sales, Net [Member]
Segment Reporting Information [Line Items]
Total revenues	49,019,000	31,809,000	132,398,000	81,804,000
Other Revenues [Member]
Segment Reporting Information [Line Items]
Total revenues	238,000	2,456,000	385,000	12,034,000
Branded [Member]
Segment Reporting Information [Line Items]
Total revenues	28,552,000	14,496,000	69,780,000	33,863,000
Cost of sales	(5,169,000)	(3,335,000)	(14,406,000)	(8,396,000)
Gross profit	23,383,000	11,161,000	55,374,000	25,467,000
Branded [Member] | Operating Segments [Member]
Operating expenses:
Selling, general and administrative	14,038,000	1,930,000	36,034,000	4,797,000
Research and development	212,000	37,000	321,000	37,000
Operating expenses	9,133,000	9,194,000	19,019,000	20,633,000
Branded [Member] | Product Sales, Net [Member]
Segment Reporting Information [Line Items]
Total revenues	28,314,000	12,040,000	69,395,000	21,829,000
Branded [Member] | Other Revenues [Member]
Segment Reporting Information [Line Items]
Total revenues	238,000	2,456,000	385,000	12,034,000
ImprimisRx [Member]
Segment Reporting Information [Line Items]
Total revenues	20,705,000	19,769,000	63,003,000	59,975,000
Cost of sales	(6,849,000)	(6,732,000)	(20,704,000)	(19,942,000)
Gross profit	13,856,000	13,037,000	42,299,000	40,033,000
ImprimisRx [Member] | Operating Segments [Member]
Operating expenses:
Selling, general and administrative	5,427,000	7,703,000	17,364,000	23,334,000
Research and development	84,000	159,000	261,000	560,000
Operating expenses	8,345,000	5,175,000	24,674,000	16,139,000
ImprimisRx [Member] | Product Sales, Net [Member]
Segment Reporting Information [Line Items]
Total revenues	20,705,000	19,769,000	63,003,000	59,975,000
ImprimisRx [Member] | Other Revenues [Member]
Segment Reporting Information [Line Items]
Total revenues
Corporate Segment [Member]
Operating expenses:
Operating expenses	14,180,000	11,400,000	40,877,000	28,747,000
Reportable Segment Aggregation Research and Development [Member]
Operating expenses:
Operating expenses	$ 1,977,000	$ 1,225,000	$ 6,893,000	$ 2,719,000

SCHEDULE OF REVENUES BY SEGMENT

SCHEDULE OF REVENUES BY SEGMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue, Major Customer [Line Items]
Revenue	$ 49,257,000	$ 34,265,000	$ 132,783,000	$ 93,838,000
Branded [Member]
Revenue, Major Customer [Line Items]
Revenue	28,552,000	14,496,000	69,780,000	33,863,000
ImprimisRx [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 20,705,000	$ 19,769,000	$ 63,003,000	$ 59,975,000
Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Branded [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	58%	42%	53%	36%
Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | ImprimisRx [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	42%	58%	47%	64%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Reportable Segment, Aggregation before Other Operating Segment [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	100%	100%	100%	100%
IHEEZO [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 12,882,000	$ 5,927,000	$ 26,498,000	$ 10,073,000
IHEEZO [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	26%	17%	20%	11%
VEVYE [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 5,186,000		$ 12,099,000
VEVYE [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	11%		9%
Other Products [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 10,256,000	$ 6,605,000	$ 30,808,000	$ 13,205,000
Other Products [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	21%	19%	23%	14%
Other Revenue [Member]
Revenue, Major Customer [Line Items]
Revenue	$ 228,000	$ 1,964,000	$ 375,000	$ 10,585,000
Other Revenue [Member] | Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]
Revenue, Major Customer [Line Items]
Revenue percentage	0%	6%	0%	11%

SEGMENTS AND CONCENTRATIONS (De

SEGMENTS AND CONCENTRATIONS (Details Narrative) - Segment	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue, Major Customer [Line Items]
Number of reportable segments			1	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Single Customer [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	46%	35%		42%	23%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Single Customer [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage				64%		80%
Purchases [Member] | Supplier Concentration Risk [Member] | Three Suppliers [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	50%	96%		51%	79%
No Products [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration risk percentage	10%	10%		10%	10%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 31, 2024	Sep. 30, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Carrying value		$ 192,750,000	$ 192,750,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Principal amount	$ 30,000,000
Carrying value	30,000,000
Payment of costs	37,000,000
Costs	150,000
Subsequent Event [Member] | Second Amendment [Member]
Subsequent Event [Line Items]
Principal amount	107,500,000
Carrying value	$ 30,000,000